A Single and Multiple Ascending Dose, Placebo-Controlled, Double-Blind, Phase 1 Study of KY1005 in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 05 Feb 2018
At a glance
- Drugs KY-1005 (Primary)
- Indications Cancer; Haematological malignancies; Inflammatory bowel diseases; Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors Kymab
- 31 Jan 2018 Treatment arm has been changed from 3 to 2 and only male volunteers participate in the clinical trial. patients number also decreases.
- 31 Jan 2018 Planned number of patients changed from 88 to 64.
- 31 Jan 2018 Planned End Date changed from 1 Apr 2018 to 1 Mar 2018.